Welcome to our dedicated page for Stryker SEC filings (Ticker: SYK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
SEC filings for Stryker are dense with surgical device specifications, FDA status updates, and acquisition details—exactly the kind of technical data investors cannot ignore. Digging for when a hip-implant recall was disclosed or how much the Mako robotic arm division contributed can mean scrolling through hundreds of pages. That complexity drives the most common questions we hear: “Where can I find Stryker’s quarterly earnings report 10-Q filing?” or “How do I track Stryker insider trading Form 4 transactions in real time?”
Stock Titan solves these challenges with AI-powered summaries that translate legal language into plain English. Open any Stryker annual report 10-K simplified by our engine and jump straight to segment revenue, R&D spend, or product liability reserves. Our platform refreshes the moment a document hits EDGAR, so you receive Stryker Form 4 insider transactions real-time, Stryker 8-K material events explained, and Stryker proxy statement executive compensation tables—Stryker SEC filings explained simply.
- AI insights highlight FDA approvals, recalls, and product-pipeline shifts hidden in 8-K filings.
- Compare Orthopaedics, MedSurg, and Neurotechnology margins across periods using interactive 10-Q analytics.
- Set alerts for Stryker executive stock transactions Form 4 to gauge management sentiment before earnings.
Whether you need understanding Stryker SEC documents with AI for due-diligence, or a quick glance at Stryker earnings report filing analysis, we provide complete coverage. Every filing type—10-K, 10-Q, 8-K, S-3, DEF 14A—is indexed, searchable, and paired with expert context on how recalls, acquisitions, or regulatory shifts may impact future cash flows. Save hours, surface the insights that matter, and make informed decisions backed by Stryker’s own disclosures.
SYK filed a Form 144 notice for a proposed secondary sale of 520,000 shares of common stock, with an aggregate market value $184,600,000. The filing lists Apex Clearing as broker and the approximate date of sale 11/05/2025 on the NYSE.
The notice also reports 382,307,000 shares outstanding as context. Acquisition history shows 10,000,000 common shares acquired on 05/01/1974 via an estate division from the Estate of L. Lee Stryker. Recent activity includes the Ronda E Stryker Revocable Trust selling 200,000 shares on 08/06/2025 for $75,283,700 in gross proceeds.
This is a resale by an existing holder; cash proceeds flow to the selling holder rather than the company.
Stryker Corporation reported an insider transaction by its VP, Chief Financial Officer on a Form 4. On 11/01/2025, the officer recorded a transaction in Common Stock with Transaction Code F, involving 404 shares at $356.24.
Following the transaction, the officer beneficially owned 6,859 shares directly and 287 shares indirectly through a 401(k). A footnote states this total includes 204 shares acquired under the Employee Stock Purchase Plan as of September 30, 2025.
Stryker (SYK) filed its Q3 2025 10‑Q reporting double‑digit top‑line growth. Net sales rose to $6,057 million from $5,494 million, and diluted EPS was $2.22 versus $2.16. For the nine months, revenue reached $17,945 million with diluted EPS of $6.20.
Growth was broad-based: MedSurg and Neurotechnology sales increased 14.4% to $3,803 million, while Orthopaedics rose 3.9% to $2,254 million. Vascular and Neuro Cranial stood out, reflecting the February acquisition of Inari Medical, which added minimally invasive venous thromboembolism products. Operating income was $1,135 million, and net earnings were $859 million.
Cash flow from operations improved to $2,901 million for the nine months, while investing cash flow of $(4,561) million reflected $4,810 million for the Inari acquisition. The company issued $3,000 million of senior notes and repaid $650 million, ending with total debt of $16,595 million and cash of $3,256 million. Stryker completed the sale of its Spinal Implants business. Shares outstanding were 382,423,648 as of September 30, 2025.
Insider transaction summary: Stryker Corporation director and Group President Viju Menon reported a sale of 500 shares of Stryker common stock on 08/25/2025 at a reported price of $390.61 per share. After the sale, Mr. Menon beneficially owns 12,511 shares directly and 197 shares indirectly through a 401(k) plan. The Form 4 was signed by an attorney-in-fact on 08/27/2025.
Stryker Corporation (SYK) Form 144 notice discloses a proposed sale of 500 shares of Stryker common stock to be executed through UBS Financial Services on 08/25/2025 on the NYSE. The securities were acquired on 03/21/2025 via PSU Vesting from Stryker Corp and paid by wire on the same acquisition date. The filing reports an aggregate market value of 195,305 for the 500 shares and shows 382,164,865 shares outstanding; no securities were reported sold in the past three months. Certain filer identification fields in the provided content (CIK and contact details) are not present in the text.
Robert S. Fletcher, VP and Chief Legal Officer of Stryker Corporation (SYK), reported an insider sale on 08/20/2025. The Form 4 shows a disposition of 1,785 shares of Stryker common stock at a reported price of $393.07 per share. After the reported sale, Mr. Fletcher beneficially owned 10,457 shares directly and 162 shares indirectly through a 401(k) account. The filing was signed on 08/21/2025 by an attorney-in-fact for Mr. Fletcher. The form indicates this was an individual filing by one reporting person and does not list any derivative transactions.
Stryker Corporation (SYK) filing a Form 144 notifies the proposed sale of 1,785 common shares through UBS Financial Services on 08/20/2025 on the NYSE. The filing reports an aggregate market value of 701,620 and shows total shares outstanding of 382,164,865. The shares were acquired via RSU vesting in three tranches: 443 shares on 08/01/2023, 908 shares on 03/21/2024, and 434 shares on 08/01/2024; payments associated with those acquisitions were by wire. The filer indicates no securities sold in the past three months and affirms they possess no undisclosed material information about the issuer.
FAQ
What is the current stock price of Stryker (SYK)?
What is the market cap of Stryker (SYK)?
